Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.

Kenneth CusiFernando BrilDiana BarbDavid C PolidoriSue ShaAtalanta GhoshKristin FarrellNishanth E SunnySrilaxmi KalavalapalliJeremy H PettusTheodore P CiaraldiSunder MudaliarRobert R Henry

Published in: Diabetes, obesity & metabolism (2018)

Canagliflozin improves hepatic insulin sensitivity and insulin secretion and clearance in patients with T2DM. IHTG decreases in proportion to the magnitude of body weight loss, which tended to be greater and occur more often with canagliflozin.

Keyphrases

weight loss
bariatric surgery
roux en y gastric bypass
gastric bypass
combination therapy
body mass index
obese patients